Published in Lab Law Weekly, August 24th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Aspreva Pharmaceuticals.
Report 1: Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) and Roche today released preliminary results for a clinical trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.
Although response rates were similar in both arms, the trial did not meet its primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly